Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Brief Summary: The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.


Options:
A: Arm Label: 60 Gy RT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Radiation: 60 Gy RT | Arm Label: 74 Gy RT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Radiation: 74 Gy RT | Arm Label: 60 Gy RT + Cetuximab; Type: EXPERIMENTAL; Interventions: Biological: Cetuximab, Drug: Carboplatin, Drug: Paclitaxel, Radiation: 60 Gy RT | Arm Label: 74 Gy RT + Cetuximab; Type: EXPERIMENTAL; Interventions: Biological: Cetuximab, Drug: Carboplatin, Drug: Paclitaxel, Radiation: 74 Gy RT | Intervention Type: BIOLOGICAL; Name: Cetuximab; Assigned to Arm(s): 60 Gy RT + Cetuximab, 74 Gy RT + Cetuximab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab, 74 Gy RT, 74 Gy RT + Cetuximab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab, 74 Gy RT, 74 Gy RT + Cetuximab | Intervention Type: RADIATION; Name: 60 Gy RT; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab | Intervention Type: RADIATION; Name: 74 Gy RT; Assigned to Arm(s): 74 Gy RT, 74 Gy RT + Cetuximab
B: Arm Label: Melanoma - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: RCC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: mCRPC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: NSCLC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: CRC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): Melanoma - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): RCC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): mCRPC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): NSCLC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): CRC - BMS-936558 (MDX-1106)
C: Arm Label: Tecemotide (L-BLP25); Type: EXPERIMENTAL; Interventions: Biological: Tecemotide (L-BLP25), Drug: Single low dose cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Tecemotide (L-BLP25); Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: B